Clinical Trial Results:
A multi-center, randomized, 12-week treatment, doubleblind study to assess the efficacy and safety of QMF149 (150/80 μg) compared with mometasone furoate (MF) Twisthaler® (200 μg) in adult and adolescent patients with asthma
Summary
|
|
EudraCT number |
2016-000472-22 |
Trial protocol |
DE EE IT SE LT SK LV HU BG PL |
Global end of trial date |
30 Nov 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
14 Jun 2019
|
First version publication date |
14 Jun 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CQVM149B2303
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02892344 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Novartis Pharmaceuticals
|
||
Sponsor organisation address |
CH-4002, Basel, Switzerland,
|
||
Public contact |
Clinical Disclosure Office, Novartis Pharmaceutical, 41 613241111,
|
||
Scientific contact |
Clinical Disclosure Office, Novartis Pharmaceuticals, 41 613241111, novartis.email@novartis.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Nov 2018
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Nov 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate the superiority of QMF149 150/80 μg o.d. (in the evening) delivered via
Concept1 compared with MF 200 μg o.d. (in the evening) delivered via Twisthaler in terms of
trough FEV1 after 12 weeks of treatment in adults and adolescents
|
||
Protection of trial subjects |
The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
17 Mar 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Bulgaria: 40
|
||
Country: Number of subjects enrolled |
Chile: 12
|
||
Country: Number of subjects enrolled |
Colombia: 7
|
||
Country: Number of subjects enrolled |
Estonia: 24
|
||
Country: Number of subjects enrolled |
Germany: 111
|
||
Country: Number of subjects enrolled |
Hungary: 116
|
||
Country: Number of subjects enrolled |
India: 73
|
||
Country: Number of subjects enrolled |
Italy: 6
|
||
Country: Number of subjects enrolled |
Japan: 52
|
||
Country: Number of subjects enrolled |
Korea, Democratic People's Republic of: 25
|
||
Country: Number of subjects enrolled |
Latvia: 44
|
||
Country: Number of subjects enrolled |
Lithuania: 2
|
||
Country: Number of subjects enrolled |
Malaysia: 3
|
||
Country: Number of subjects enrolled |
Peru: 54
|
||
Country: Number of subjects enrolled |
Philippines: 11
|
||
Country: Number of subjects enrolled |
Poland: 50
|
||
Country: Number of subjects enrolled |
Russian Federation: 34
|
||
Country: Number of subjects enrolled |
Slovakia: 80
|
||
Country: Number of subjects enrolled |
South Africa: 23
|
||
Country: Number of subjects enrolled |
Sweden: 2
|
||
Country: Number of subjects enrolled |
Thailand: 11
|
||
Country: Number of subjects enrolled |
Vietnam: 22
|
||
Worldwide total number of subjects |
802
|
||
EEA total number of subjects |
475
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
64
|
||
Adults (18-64 years) |
630
|
||
From 65 to 84 years |
108
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||
Screening details |
This study used a 12-week treatment, randomized, double-blind, double-dummy, parallel-group design. The 12 week treatment epoch was followed by a 30 day Follow-up epoch. | ||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||
Arm title
|
QMF149 150/80 μg | ||||||||||||||||||||||||||||||||||||
Arm description |
QMF149 150/80 microgram o.d. delivered via Concept1 | ||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
QMF149 150/80 μg
|
||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
QMF149 150/80 μg
|
||||||||||||||||||||||||||||||||||||
Other name |
QMF149 150/80 μg
|
||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Inhalation powder, hard capsule
|
||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||
Dosage and administration details |
QMF149 150/80 μg o.d. delivered via Concept1
|
||||||||||||||||||||||||||||||||||||
Arm title
|
MF 200 µg | ||||||||||||||||||||||||||||||||||||
Arm description |
MF 200 microgram o.d. delivered via Twisthaler® | ||||||||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
MF 200 µg
|
||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
MF 200 µg
|
||||||||||||||||||||||||||||||||||||
Other name |
MF 200 µg
|
||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Inhalation powder, hard capsule
|
||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||
Dosage and administration details |
MF 200 μg o.d. delivered via a Twisthaler
|
||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
QMF149 150/80 μg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
QMF149 150/80 microgram o.d. delivered via Concept1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
MF 200 µg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
MF 200 microgram o.d. delivered via Twisthaler® | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
QMF149 150/80 μg
|
||
Reporting group description |
QMF149 150/80 microgram o.d. delivered via Concept1 | ||
Reporting group title |
MF 200 µg
|
||
Reporting group description |
MF 200 microgram o.d. delivered via Twisthaler® |
|
|||||||||||||
End point title |
trough FEV1 | ||||||||||||
End point description |
demonstrate the superiority of QMF149 150/80 microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d. (in the evening) delivered via Twisthaler® in terms of trough FEV1 after 12 weeks of treatment in adults and adolescents. Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured by spirometry.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
week 12
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Trough FEV1 | ||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||
Number of subjects included in analysis |
752
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
0.182
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.148 | ||||||||||||
upper limit |
0.217 |
|
|||||||||||||
End point title |
ACQ-7 | ||||||||||||
End point description |
ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control. the ACQ-7 was used to assess improvements in asthma symptom control. The ACQ-7, a seven-item disease-specific instrument developed and validated to assess asthma control in patients in clinical trials as well as in individuals in clinical practice, was provided to the site. All seven items were then scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating no control. The questions were equally weighted and the total score was the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the patient while the last question (question 7) was completed by the study investigator using spirometry data generated by the spirometry equipment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
week 12
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
ACQ-7 | ||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||
Number of subjects included in analysis |
744
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
-0.218
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.293 | ||||||||||||
upper limit |
-0.143 |
|
|||||||||||||
End point title |
trough FEV1 at day 2 | ||||||||||||
End point description |
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 2
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
trough FEV1 at day 2 | ||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||
Number of subjects included in analysis |
782
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
0.132
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.105 | ||||||||||||
upper limit |
0.158 |
|
|||||||||||||
End point title |
Pre-dose FEV1 at week 4 | ||||||||||||
End point description |
Pre-dose FEV1 is defined as the mean of -45 min and -15 min FEV1 values pre-evening dose
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
week 4
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Pre-dose FEV1 at week 4 | ||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||
Number of subjects included in analysis |
775
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
0.176
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.145 | ||||||||||||
upper limit |
0.207 |
|
|||||||||||||||||||
End point title |
FVC over 12 weeks | ||||||||||||||||||
End point description |
FVC is the total amount of air exhaled during the FEV test. Forced Vital Capacity (FVC) and Forced Expiratory Flow between 25% and 75% of FVC (FEF25-75) will be measured
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
week 12
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Pre-dose trough FEF25-75% | ||||||||||||||||||
Statistical analysis description |
Pre-dose trough FEF25-75%
|
||||||||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||||||||
Number of subjects included in analysis |
762
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
|||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||
Point estimate |
0.288
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.231 | ||||||||||||||||||
upper limit |
0.345 | ||||||||||||||||||
Statistical analysis title |
Pre-dose trough FVC | ||||||||||||||||||
Statistical analysis description |
Pre-dose trough FVC
|
||||||||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||||||||
Number of subjects included in analysis |
762
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
|||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||
Point estimate |
0.1
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.061 | ||||||||||||||||||
upper limit |
0.139 |
|
|||||||||||||||||||
End point title |
PEF over 4 and 12 weeks | ||||||||||||||||||
End point description |
Morning and Evening Peak Expiratory Flow Rate (PEF) will be measured. PEF is the peak expiratory flow, the maximum speed of expiration
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
week 12
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Mean Morning PEF | ||||||||||||||||||
Statistical analysis description |
Mean Morning PEF
|
||||||||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||||||||
Number of subjects included in analysis |
802
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
|||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||
Point estimate |
27.2
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
22.1 | ||||||||||||||||||
upper limit |
32.4 | ||||||||||||||||||
Statistical analysis title |
Mean Evening PEF | ||||||||||||||||||
Statistical analysis description |
Mean Evening PEF
|
||||||||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||||||||
Number of subjects included in analysis |
802
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
|||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||
Point estimate |
26.1
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
21 | ||||||||||||||||||
upper limit |
31.2 |
|
|||||||||||||
End point title |
Percentage of patients with ACQ-7 MID at week 12 | ||||||||||||
End point description |
MID is Minimum Important Difference. ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control. Percent of patients achieving the minimal important difference (MID) in ACQ-7 (i.e. at least 0.5 decrease from baseline) will be measured.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
week 12
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Daily e-diary over 12 weeks | |||||||||||||||||||||
End point description |
Percentage of asthma symptoms free days, the percentage of nights without nighttime awakenings, and the percentage of mornings without symptoms on awakening as recorded by daily electronic Diary (e-Diary) over 12 weeks of treatment
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
week 12
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
ACQ-7 at week 4 | ||||||||||||
End point description |
ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
week 4
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
ACQ-7 at week 4 | ||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||
Number of subjects included in analysis |
750
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
-0.204
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.277 | ||||||||||||
upper limit |
-0.131 |
|
|||||||||||||||||||
End point title |
Rescue medication use over 12 weeks | ||||||||||||||||||
End point description |
Rescue salbutamol/albuterol usage (mean daily, nighttime and daytime use) from e-Diary recordings over 12 weeks of treatment
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
week 12
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Night-time number of puffs of rescue medication | ||||||||||||||||||
Statistical analysis description |
Night-time number of puffs of rescue medication
|
||||||||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||||||||
Number of subjects included in analysis |
802
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
|||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||
Point estimate |
-0.11
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-0.16 | ||||||||||||||||||
upper limit |
-0.05 | ||||||||||||||||||
Statistical analysis title |
Daytime number of puffs of rescue medication | ||||||||||||||||||
Statistical analysis description |
Daytime number of puffs of rescue medication
|
||||||||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||||||||
Number of subjects included in analysis |
802
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
|||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||
Point estimate |
-0.15
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-0.22 | ||||||||||||||||||
upper limit |
-0.08 |
|
|||||||||||||
End point title |
Percentage of rescue medication free days over 12 weeks | ||||||||||||
End point description |
Percentage of rescue medication free days over 12 weeks of treatment period
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
week 12
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Percentage of rescue medication free days | ||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||
Number of subjects included in analysis |
769
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
8.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
4.3 | ||||||||||||
upper limit |
11.8 |
|
|||||||||||||
End point title |
Quality of life assessed by AQLQ-S 12 | ||||||||||||
End point description |
The AQLQ-S +12 is a 32-item disease specific questionnaire designed to measure functional impairments that were most important to patients with asthma. It consists of 4 domains: symptoms, emotions, exposure to environmental stimuli and activity limitation
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
week 12
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Quality of life assessed by AQLQ-S 12 | ||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||
Number of subjects included in analysis |
760
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
0.149
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.064 | ||||||||||||
upper limit |
0.234 |
|
||||||||||||||||||||||
End point title |
Asthma exacerbation over 12 weeks | |||||||||||||||||||||
End point description |
The exacerbation categories are: mild, moderate, severe and the combination of moderate or severe. Time to first asthma exacerbation by exacerbation category. Annual rate of asthma exacerbations by exacerbation category.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Week 12
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
The Annual Rate of Asthma Exacerbations (Moderate or Severe) Over the 12 Week Treatment Period | ||||||||||||||||||
End point description |
Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS (Systemic Corticosteroids) use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Time to first Asthma Exacerbations (Moderate or Severe) Over the 12 Week Treatment Period | ||||||||||||
End point description |
Defined as the number of days from start of treatment up to the first date when an asthma exacerbation occurs.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 12
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
The annual rate of asthma exacerbations | ||||||||||||
Comparison groups |
QMF149 150/80 μg v MF 200 µg
|
||||||||||||
Number of subjects included in analysis |
791
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Regression, Cox | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.29
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.14 | ||||||||||||
upper limit |
0.59 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Timeframe for AE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
AE additional description
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
21.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
MF 200
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
MF 200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
QMF149 150/80
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
QMF149 150/80 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
25 May 2017 |
Adjust the approach to asthma worsening eDiary
alerts during the Run-in epoch. It was earlier stated
in the protocol, that if an asthma worsening alert is
observed during the Run-in epoch, the patients
must be discontinued regardless of clinical context
and investigator judgment. This protocol
amendment allowed investigators to use their
discretion in determining the clinical significance of
asthma worsening eDiary alerts during the Run-in
epoch. This allowed the investigator to make the
most appropriate decision as to whether patients
may continue in the study or be discontinued. If
asthma worsening alert was confirmed as clinically
significant by the investigator, patients should be
discontinued. A combination of eDiary alerts and
investigator judgment was expected to help ensure
that the most appropriate patients were enrolled in
the study, while maintaining rigorous monitoring
and assessment of patient safety |
||
20 Mar 2018 |
The assumptions for Study B2303 key secondary
endpoint, ACQ-7 treatment difference, were originally
based on data from QMF149 Study A2210. In study
A2210, the observed mean difference after 12 weeks of
treatment (QMF149 vs MF) was −0.21 with 95% CI
(−0.28, −0.15). Based on the upper limit of the CI, a
treatment difference of −0.15 was chosen as a
conservative estimate, which was used to determine
the sample size of Study B2303. However, upon recent
evaluation of the treatment difference of Study A2210, it
was decided to adopt an ACQ-7 treatment difference of
−0.18. This treatment difference is the upper limit of the
one-sided 80% CI and more appropriately reflects the
expected improvement in ACQ-7 for the patient
population of Study B2303. Reflecting the revised
assumptions, the sample size re-estimation has
allowed for a reduction from 1000 to approximately 750
patients. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |